CO2019001319A2 - Method and system for microbial pharmacogenomics - Google Patents

Method and system for microbial pharmacogenomics

Info

Publication number
CO2019001319A2
CO2019001319A2 CONC2019/0001319A CO2019001319A CO2019001319A2 CO 2019001319 A2 CO2019001319 A2 CO 2019001319A2 CO 2019001319 A CO2019001319 A CO 2019001319A CO 2019001319 A2 CO2019001319 A2 CO 2019001319A2
Authority
CO
Colombia
Prior art keywords
antibiotics
microbiome
operable
user
data
Prior art date
Application number
CONC2019/0001319A
Other languages
Spanish (es)
Inventor
Daniel Almonacid
Zachary Apte
Jessica Richman
Inti Pedroso
Juan Ugalde
Rodrigo Ortiz
Original Assignee
Ubiome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/606,743 external-priority patent/US10803991B2/en
Application filed by Ubiome Inc filed Critical Ubiome Inc
Publication of CO2019001319A2 publication Critical patent/CO2019001319A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/746—Alarms related to a physiological condition, e.g. details of setting alarm thresholds or avoiding false alarms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/74—Details of notification to user or communication with user or patient ; user input means
    • A61B5/7465—Arrangements for interactive communication between patient and care services, e.g. by using a telephone network
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Nursing (AREA)
  • Physiology (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)

Abstract

Realizaciones de un método y sistema para farmacogenómicas microbianas pueden incluir: un sistema de manejo de muestras operables para colectar contenedores que incluyen muestras biológicas desde un grupo de usuarios, el sistema de manejo que incluye un sistema de secuenciación a partir de muestras biológicas; un sistema de caracterización de microbioma operable para: determinar datos farmacogenómicos del microbioma basado en las secuencias de microorganismos, colectar datos suplementarios asociados con la condición asociada a antibióticos para el grupo de usuarios, y transformar los datos suplementarios y características extraídas de los datos farmacogenómicos de del microbioma en un modelo de caracterización asociado con la condición relacionada a antibióticos; y un sistema de tratamiento operable para promover un tratamiento al usuario para la condición asociada a antibióticos basado en caracterizar el material biológico del usuario con el modelo de caracterización en relación a la condición asociada a antibióticos.Embodiments of a method and system for microbial pharmacogenomics may include: a operable sample management system for collecting containers that include biological samples from a group of users, the management system that includes a sequencing system from biological samples; a microbiome characterization system operable to: determine pharmacogenomic data of the microbiome based on the sequences of microorganisms, collect supplementary data associated with the condition associated with antibiotics for the user group, and transform the supplementary data and characteristics extracted from the pharmacogenomic data of of the microbiome in a characterization model associated with the antibiotic related condition; and an operable treatment system to promote a treatment to the user for the condition associated with antibiotics based on characterizing the biological material of the user with the characterization model in relation to the condition associated with antibiotics.

CONC2019/0001319A 2016-07-13 2019-02-13 Method and system for microbial pharmacogenomics CO2019001319A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662361943P 2016-07-13 2016-07-13
US15/606,743 US10803991B2 (en) 2014-10-21 2017-05-26 Method and system for microbiome-derived diagnostics and therapeutics
PCT/US2017/042015 WO2018013865A1 (en) 2016-07-13 2017-07-13 Method and system for microbial pharmacogenomics

Publications (1)

Publication Number Publication Date
CO2019001319A2 true CO2019001319A2 (en) 2019-02-19

Family

ID=60953350

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0001319A CO2019001319A2 (en) 2016-07-13 2019-02-13 Method and system for microbial pharmacogenomics

Country Status (12)

Country Link
EP (1) EP3484348A4 (en)
JP (2) JP2019521706A (en)
KR (1) KR102397683B1 (en)
CN (1) CN109475305B (en)
AU (1) AU2017295861A1 (en)
BR (1) BR112019000709A8 (en)
CA (1) CA3030792A1 (en)
CO (1) CO2019001319A2 (en)
EA (1) EA201990294A1 (en)
SG (1) SG11201900253TA (en)
WO (1) WO2018013865A1 (en)
ZA (1) ZA201900473B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200397732A1 (en) * 2017-12-04 2020-12-24 Cybele Microbiome, Inc. Methods and compositions for identification and modulation of microbiome biochemical pathways to alter phenotype
AU2019233926A1 (en) * 2018-03-16 2020-06-18 Psomagen, Inc. Method and system for characterization of metabolism-associated conditions, including diagnostics and therapies, based on bioinformatics approach
JP7455757B2 (en) * 2018-04-13 2024-03-26 フリーノーム・ホールディングス・インコーポレイテッド Machine learning implementation for multianalyte assay of biological samples
KR102346398B1 (en) 2020-09-01 2022-01-03 주식회사 에이아이바이오틱스 System For Analyzing and Evaluating Gut Microbiome And Evaluation Method For The Same
US20220367050A1 (en) * 2021-05-12 2022-11-17 Zoe Limited Predicting gut microbiome diversity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2178101T3 (en) * 1994-12-09 2002-12-16 Imp College Innovations Ltd VIRULENCE GENES IN THE VGC2 REGION OF SALMONELLA.
US9107831B2 (en) * 2003-06-02 2015-08-18 Novartis Vaccines And Diagonstics, Inc. Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens
WO2007048436A1 (en) * 2005-10-29 2007-05-03 Bayer Technology Services Gmbh Process for determining one or more analytes in samples of biological origin having complex composition, and use thereof
EP2799557B1 (en) * 2008-02-28 2016-09-07 The Ohio State University Research Foundation MiR-32 antagonists for increasing responsiveness of prostate cancer to apoptosis
CA2742598A1 (en) * 2008-11-04 2010-05-14 Blood Cell Storage, Inc. Nucleic acid extraction on curved glass surfaces
EP2450080A4 (en) * 2010-01-29 2013-05-29 Ubiomed Inc Micro needle and micro needle device
PT2547361T (en) * 2010-03-17 2020-12-07 Socpra Sciences Et Genie Sec Bacterial vaccine components from staphylococcus aureus and uses thereof
CN101833613A (en) * 2010-06-04 2010-09-15 中国科学院青岛生物能源与过程研究所 Oral microbial community database and application thereof
US20130121968A1 (en) * 2011-10-03 2013-05-16 Atossa Genetics, Inc. Methods of combining metagenome and the metatranscriptome in multiplex profiles
WO2013176774A1 (en) * 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US20140143188A1 (en) * 2012-11-16 2014-05-22 Genformatic, Llc Method of machine learning, employing bayesian latent class inference: combining multiple genomic feature detection algorithms to produce an integrated genomic feature set with specificity, sensitivity and accuracy
CN110917220A (en) * 2013-02-04 2020-03-27 赛里斯治疗公司 Therapeutic compositions and methods of use thereof
US9466024B2 (en) * 2013-03-15 2016-10-11 Northrop Grumman Systems Corporation Learning health systems and methods
EP2968757A4 (en) * 2013-03-15 2016-10-12 Prometheon Pharma Llc Devices, systems, and methods for transdermal delivery of compounds
CA2917231A1 (en) * 2013-07-01 2015-01-08 Ixcela, Inc. Systems biology approach to therapy
CN105407728A (en) * 2013-07-21 2016-03-16 霍勒拜欧姆公司 Methods and systems for microbiome characterization, monitoring and treatment
US10920283B2 (en) * 2013-11-01 2021-02-16 Washington University Methods to establish and restore normal gut microbiota function of subject in need thereof
US9663831B2 (en) * 2014-01-25 2017-05-30 uBiome, Inc. Method and system for microbiome analysis
WO2016057679A1 (en) * 2014-10-09 2016-04-14 LuminaCare Solutions Inc. Personalized antibiotic dosing platform
AU2015335907A1 (en) * 2014-10-21 2017-04-13 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics
AU2015358251A1 (en) * 2014-12-05 2017-06-29 University Of Saskatchewan Methods and reagents for detecting neisseria gonorrhoeae and its antimicrobial resistance determinants
CN105648060B (en) * 2016-01-29 2020-01-31 江汉大学 Method for detecting drug-resistant genes of non-diagnostic human pathogenic microorganisms

Also Published As

Publication number Publication date
CA3030792A1 (en) 2018-01-18
SG11201900253TA (en) 2019-02-27
EP3484348A1 (en) 2019-05-22
EA201990294A1 (en) 2019-08-30
BR112019000709A2 (en) 2019-05-14
BR112019000709A8 (en) 2023-03-21
EP3484348A4 (en) 2021-11-24
KR102397683B1 (en) 2022-05-13
CN109475305B (en) 2022-01-25
AU2017295861A1 (en) 2019-01-24
WO2018013865A1 (en) 2018-01-18
JP2019521706A (en) 2019-08-08
CN109475305A (en) 2019-03-15
ZA201900473B (en) 2019-09-25
KR20190033561A (en) 2019-03-29
JP2022079646A (en) 2022-05-26

Similar Documents

Publication Publication Date Title
CO2019001319A2 (en) Method and system for microbial pharmacogenomics
WO2015112352A8 (en) Method and system for microbiome analysis
EA201991662A1 (en) NEW SYSTEMS AND FERMENTATION METHODS
AU2018323509A1 (en) Method and system for characterization for female reproductive system-related conditions associated with microorganisms
MX2016016902A (en) Methods of analyzing nucleic acids from individual cells or cell populations.
MX2016014496A (en) Specimen collection device.
AR113772A1 (en) BIOREACTOR FOR PERFUSION AND RELATED METHODS OF USE
NZ731116A (en) Method for the enrichment of circulating tumor dna
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
CO2019003713A2 (en) Method and system for panel characterizations
WO2016012459A3 (en) Parallel cell processing method and facility
MX2019003927A (en) Analysis system and method for testing a sample.
MX354956B (en) Context-based object retrieval in a social networking system.
BR112019005167A2 (en) method and kit for analyzing a sample
BR112019005172A2 (en) method and kit for analyzing a sample
AU2016250096A8 (en) Method and system for microbiome-derived characterization, diagnostics and therapeutics for conditions associated with functional features
BR112014026440A8 (en) analysis, methods and apparatus for the evaluation of RNA disruption.
BR112019006862A2 (en) Analysis device and method for testing a sample
WO2016168359A8 (en) Method and system for microbiome-derived diagnostics and therapeutics for mental health associated conditions
MX2016016469A (en) Sample holder for biological samples.
BR112016028185A2 (en) method for producing an 1-amino acid.
ES2618834T3 (en) Method for the simultaneous detection of bacteria and fungi in a biological preparation by PCR, primers as well as bacteria and fungus detection kit
WO2016051177A3 (en) Methods and kits
WO2015187953A8 (en) Method for direct microbial identification
GB2538006A (en) Gene expression profiles associated with sub-clinical kidney transplant rejection